Abstract
An 81-year-old woman developed symptomatic liver disease 3 weeks after beginning clopidogrel as adjunctive antiplatelet therapy for a coronary stent implantation. Symptomatic liver disease associated with short-term periprocedural administration of clopidogrel for coronary stenting has not been well described. The clinical significance of this event as well as a possible interaction between clopidogrel and other drugs metabolized by the cytochrome P450 2C9 pathways coadministered to this patient are discussed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 317-318 |
| Number of pages | 2 |
| Journal | American journal of therapeutics |
| Volume | 7 |
| Issue number | 5 |
| DOIs | |
| State | Published - Jan 1 2000 |
Keywords
- Clopidogrel
- Drug-induced hepatotoxicity
ASJC Scopus subject areas
- Pharmacology
Fingerprint Dive into the research topics of 'Clopidogrel-induced mixed hepatocellular and cholestatic liver injury'. Together they form a unique fingerprint.
Cite this
Willens, H. J. (2000). Clopidogrel-induced mixed hepatocellular and cholestatic liver injury. American journal of therapeutics, 7(5), 317-318. https://doi.org/10.1097/00045391-200007050-00009